The abstract is read at the publisher; the summary is JClub's.
Elevated IL12/IL23 p40 in patients’ serum rises shortly after starting anti-PD-1 plus anti-CTLA-4, before clinically apparent irAEs, without being linked to ICB efficacy.
- Why it matters: Immune checkpoint blockade improves survival but can trigger severe, sometimes fatal irAEs, and current immunosuppression may reduce antitumor benefit; early drivers are unclear.
- What they did: The study used serum proteomic analyses in patients receiving combined anti-PD-1 and anti-CTLA-4, then tested p40 neutralization in multiple mouse models for toxicity and antitumor effects.
- The result: Blocking p40 mitigated ICB-induced toxicity across mouse models while preserving ICB antitumor efficacy, supporting p40 blockade as a strategy to prevent irAEs during ICB.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.